Press Releases

MYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct Clinical Metabolomic Studies in Subjects Using Fortetropin(TM)

Download PDF

MYOS Exploring Potential Role of Myostatin Inhibiting Product on Glucose and Fat Metabolism

CEDAR KNOLLS, NJ -- (Marketwired) -- 09/18/14 -- MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research agreement with Human Metabolome Technologies America, Inc. ("HMT"). Founded in 2003, HMT is a global leader in the emerging fields of metabolomics and systems biology. HMT will apply their proprietary, state-of-the-art capillary electrophoresis-mass spectrometry (CE-MS) technologies to characterize the metabolomic profiles of plasma samples obtained from healthy male subjects who used either Fortetropin or placebo with the goal of identifying metabolites with pro-myogenic activity in the plasma samples of subjects who took Fortetropin as well as examining the effect on glucose and fat metabolism.

Results from prior clinical studies of Fortetropin demonstrated that this myostatin inhibiting product had significant benefits in producing lean body mass and reducing body fat mass. The potential clinical implications of these observations may represent important new uses for the product in the treatment of obesity and diabetes. MYOS anticipates that the results from this comparative metabolomic study of Fortetropin and placebo will enhance its understanding of the mechanism of action of Fortetropin and provide guidance for development of biotherapeutics based on Fortetropin. Additionally, the early indications of plasma biomarkers may guide future study design for Fortetropin clinical trials by identifying clinically-relevant endpoints and potential stratification of patient populations. HMT will use a metabolite database of over 290 lipids and over 900 metabolites which may be potential plasma biomarkers of muscle growth.

Tsutomu Hoshiba, President of HMT, commented, "We are thrilled that MYOS is partnering with HMT to leverage our expertise and state-of the-art technologies in metabolomics. For the aging population there is an urgent need to address muscle wasting diseases such as sarcopenia and frailty. MYOS is taking an innovative approach to addressing this need through the development of novel dietary supplements and therapeutic products."

Robert C. Ashton, Jr., M.D., Chief Medical Officer at MYOS commented, "We believe our research collaboration with HMT will deepen our understanding of the metabolic impact of Fortetropin in humans and provide a basis for further studies which may create a path to using this product as an adjunct to the treatment of diabetes, cachexia and even obesity. In addition, we believe this collaboration will help us better understand the pro-myogenic milieu and identify potential biomarkers which may strengthen future research. We hope these data will enable MYOS to provide a compelling scientific rationale for the use of Fortetropin to address the unmet need for a safe and effective treatment for sarcopenia as well as in the management of muscle wasting seen in cachexia of chronic illness."

The Company expects to receive the results of this study in the fourth quarter of 2014.

About Human Metabolome Technologies America
Human Metabolome Technologies (HMT) is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions to drive drug discovery, diagnosis, and food production. HMT can identify more than 1,000 species of metabolites by the metabolome analysis technology using CE-MS. In addition, HMT has developed an original software analysis platform along with the measuring technologies, such as CE-MS, LC-MS, and MS/MS, for the realization of metabolome analysis.

About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company," visit

The Company's first commercial product containing Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including,, and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin and its effects on myostatin inhibition, including our research and development activities described herein, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

MYOS Corporation Investor and Media Contact:

Jenene Thomas
Investor Relations and Corporate Communications
(973) 509-0444
Email Contact

Source: MYOS Corporation